Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1996 Aug;64(8):3244–3251. doi: 10.1128/iai.64.8.3244-3251.1996

Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

M B Kurtz 1, G Abruzzo 1, A Flattery 1, K Bartizal 1, J A Marrinan 1, W Li 1, J Milligan 1, K Nollstadt 1, C M Douglas 1
PMCID: PMC174214  PMID: 8757860

Abstract

The pneumocandins are potent antifungal agents of the echinocandin class which are under development for use as broad-spectrum antimycotic therapy. One important consideration for any new therapeutic class for treating serious fungal infections is the potential for drug resistance development. In this study we have isolated and characterized four independent spontaneous Candida albicans mutants resistant to the potent semisynthetic pneumocandin L-733,560. These mutants have many of the properties of FKS1/ETG1 echinocandin-resistant mutants of Saccharomyces cerevisiae, including (i) cross-resistance to other 1,3-beta-D-glucan synthase inhibitors, such as papulacandin and echinocandins, but no change in sensitivity to other antifungal agents; (ii) in vitro glucan synthase activity that is more resistant to pneumocandins than the wild-type parent enzyme; and (iii) semidominant drug resistance in spheroplast fusion strains. The mutants were compared with C. albicans echinocandin-resistant mutants isolated by mutagenesis by L. Beckford and D. Kerridge (mutant M-2) (abstr. PS3.11, in Proceedings of the XI Congress of the International Society for Human and Animal Mycology, Montreal, Canada, 1992) and by A. Cassone, R. E. Mason, and D. Kerridge (mutant CA-2) (Sabouraudia 19:97-110, 1981). All of the strains had resistant enzyme activity in vitro. M-2 grew poorly and had low levels of enzyme activity. In contrast, CA-2 and the spontaneous mutants grew as well as the parents and had normal levels of glucan synthase activity. These results suggest that these resistant mutants may have alterations in glucan synthase. CA-2 was unable to form germ tubes, an ability retained by the spontaneous mutants. The virulence of the spontaneous mutants was unimpaired in a mouse model of disseminated candidiasis, while M-2 and CA-2 were 2 orders of magnitude less virulent than their parent strains. Significantly, mice challenged with the spontaneous mutant CAI4R1 responded therapeutically to lower levels of L-733,560 than would he predicted by the increase in in vitro susceptibility.

Full Text

The Full Text of this article is available as a PDF (262.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abruzzo G. K., Flattery A. M., Gill C. J., Kong L., Smith J. G., Krupa D., Pikounis V. B., Kropp H., Bartizal K. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1995 May;39(5):1077–1081. doi: 10.1128/aac.39.5.1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Angiolella L., Simonetti N., Cassone A. The lipopeptide antimycotic, cilofungin modulates the incorporation of glucan-associated proteins into the cell wall of Candida albicans. J Antimicrob Chemother. 1994 Jun;33(6):1137–1146. doi: 10.1093/jac/33.6.1137. [DOI] [PubMed] [Google Scholar]
  3. Bartizal K., Abruzzo G., Trainor C., Krupa D., Nollstadt K., Schmatz D., Schwartz R., Hammond M., Balkovec J., Vanmiddlesworth F. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother. 1992 Aug;36(8):1648–1657. doi: 10.1128/aac.36.8.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beaulieu D., Tang J., Zeckner D. J., Parr T. R., Jr Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. FEMS Microbiol Lett. 1993 Apr 1;108(2):133–137. doi: 10.1111/j.1574-6968.1993.tb06088.x. [DOI] [PubMed] [Google Scholar]
  5. Boeke J. D., LaCroute F., Fink G. R. A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Mol Gen Genet. 1984;197(2):345–346. doi: 10.1007/BF00330984. [DOI] [PubMed] [Google Scholar]
  6. Bouffard F. A., Zambias R. A., Dropinski J. F., Balkovec J. M., Hammond M. L., Abruzzo G. K., Bartizal K. F., Marrinan J. A., Kurtz M. B., McFadden D. C. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem. 1994 Jan 21;37(2):222–225. doi: 10.1021/jm00028a003. [DOI] [PubMed] [Google Scholar]
  7. Cassone A., Mason R. E., Kerridge D. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. Sabouraudia. 1981 Jun;19(2):97–110. [PubMed] [Google Scholar]
  8. Castro C., Ribas J. C., Valdivieso M. H., Varona R., del Rey F., Duran A. Papulacandin B resistance in budding and fission yeasts: isolation and characterization of a gene involved in (1,3)beta-D-glucan synthesis in Saccharomyces cerevisiae. J Bacteriol. 1995 Oct;177(20):5732–5739. doi: 10.1128/jb.177.20.5732-5739.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Conly J., Rennie R., Johnson J., Farah S., Hellman L. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis. 1992 Apr;165(4):761–764. doi: 10.1093/infdis/165.4.761. [DOI] [PubMed] [Google Scholar]
  10. De Bernardis F., Adriani D., Lorenzini R., Pontieri E., Carruba G., Cassone A. Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection. Infect Immun. 1993 Apr;61(4):1500–1508. doi: 10.1128/iai.61.4.1500-1508.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Defever K. S., Whelan W. L., Rogers A. L., Beneke E. S., Veselenak J. M., Soll D. R. Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates. Antimicrob Agents Chemother. 1982 Nov;22(5):810–815. doi: 10.1128/aac.22.5.810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Denning D. W., Stevens D. A. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 1991 Jul;35(7):1329–1333. doi: 10.1128/aac.35.7.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Douglas C. M., Foor F., Marrinan J. A., Morin N., Nielsen J. B., Dahl A. M., Mazur P., Baginsky W., Li W., el-Sherbeini M. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12907–12911. doi: 10.1073/pnas.91.26.12907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Douglas C. M., Marrinan J. A., Li W., Kurtz M. B. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol. 1994 Sep;176(18):5686–5696. doi: 10.1128/jb.176.18.5686-5696.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Font de Mora J., Gil R., Sentandreu R., Herrero E. Isolation and characterization of Saccharomyces cerevisiae mutants resistant to aculeacin A. Antimicrob Agents Chemother. 1991 Dec;35(12):2596–2601. doi: 10.1128/aac.35.12.2596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fonzi W. A., Irwin M. Y. Isogenic strain construction and gene mapping in Candida albicans. Genetics. 1993 Jul;134(3):717–728. doi: 10.1093/genetics/134.3.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gordee R. S., Zeckner D. J., Ellis L. F., Thakkar A. L., Howard L. C. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J Antibiot (Tokyo) 1984 Sep;37(9):1054–1065. doi: 10.7164/antibiotics.37.1054. [DOI] [PubMed] [Google Scholar]
  18. Goshorn A. K., Scherer S. Genetic analysis of prototrophic natural variants of Candida albicans. Genetics. 1989 Dec;123(4):667–673. doi: 10.1093/genetics/123.4.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gow N. A., Robbins P. W., Lester J. W., Brown A. J., Fonzi W. A., Chapman T., Kinsman O. S. A hyphal-specific chitin synthase gene (CHS2) is not essential for growth, dimorphism, or virulence of Candida albicans. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6216–6220. doi: 10.1073/pnas.91.13.6216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hilton C., Markie D., Corner B., Rikkerink E., Poulter R. Heat shock induces chromosome loss in the yeast Candida albicans. Mol Gen Genet. 1985;200(1):162–168. doi: 10.1007/BF00383330. [DOI] [PubMed] [Google Scholar]
  21. Hitchcock C. A. Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans. 1993 Nov;21(4):1039–1047. doi: 10.1042/bst0211039. [DOI] [PubMed] [Google Scholar]
  22. Inoue S. B., Takewaki N., Takasuka T., Mio T., Adachi M., Fujii Y., Miyamoto C., Arisawa M., Furuichi Y., Watanabe T. Characterization and gene cloning of 1,3-beta-D-glucan synthase from Saccharomyces cerevisiae. Eur J Biochem. 1995 Aug 1;231(3):845–854. doi: 10.1111/j.1432-1033.1995.tb20770.x. [DOI] [PubMed] [Google Scholar]
  23. Kirsch D. R., Whitney R. R. Pathogenicity of Candida albicans auxotrophic mutants in experimental infections. Infect Immun. 1991 Sep;59(9):3297–3300. doi: 10.1128/iai.59.9.3297-3300.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kurtz M. B., Cortelyou M. W., Kirsch D. R. Integrative transformation of Candida albicans, using a cloned Candida ADE2 gene. Mol Cell Biol. 1986 Jan;6(1):142–149. doi: 10.1128/mcb.6.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kurtz M. B., Douglas C., Marrinan J., Nollstadt K., Onishi J., Dreikorn S., Milligan J., Mandala S., Thompson J., Balkovec J. M. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother. 1994 Dec;38(12):2750–2757. doi: 10.1128/aac.38.12.2750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Magee B. B., Koltin Y., Gorman J. A., Magee P. T. Assignment of cloned genes to the seven electrophoretically separated Candida albicans chromosomes. Mol Cell Biol. 1988 Nov;8(11):4721–4726. doi: 10.1128/mcb.8.11.4721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mazur P., Morin N., Baginsky W., el-Sherbeini M., Clemas J. A., Nielsen J. B., Foor F. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol. 1995 Oct;15(10):5671–5681. doi: 10.1128/mcb.15.10.5671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. McIntyre K. A., Galgiani J. N. pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother. 1989 May;33(5):731–735. doi: 10.1128/aac.33.5.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mehta R. J., Nash C. H., Grappel S. F., Actor P. Aculeacin A resistant mutants of Candida albicans. J Antibiot (Tokyo) 1982 Jun;35(6):707–711. doi: 10.7164/antibiotics.35.707. [DOI] [PubMed] [Google Scholar]
  30. Mizuno K., Yagi A., Satoi S., Takada M., Hayashi M. Studies on aculeacin. I. Isolation and characterization of aculeacin A. J Antibiot (Tokyo) 1977 Apr;30(4):297–302. doi: 10.7164/antibiotics.30.297. [DOI] [PubMed] [Google Scholar]
  31. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  32. Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ribas J. C., Roncero C., Rico H., Durán A. Characterization of a Schizosaccharomyces pombe morphological mutant altered in the galactomannan content. FEMS Microbiol Lett. 1991 Apr 15;63(2-3):263–267. doi: 10.1016/0378-1097(91)90096-s. [DOI] [PubMed] [Google Scholar]
  34. Røder B. L., Sonnenschein C., Hartzen S. H. Failure of fluconazole therapy in Candida krusei fungemia. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):173–173. doi: 10.1007/BF01964453. [DOI] [PubMed] [Google Scholar]
  35. Sanguineti A., Carmichael J. K., Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med. 1993 May 10;153(9):1122–1124. [PubMed] [Google Scholar]
  36. Sarachek A., Henderson L. A. Variations for susceptibilities to ultraviolet induced cellular inactivation and gene segregation among protoplast fusion hybrids of Candida albicans. Cytobios. 1988;55(222-223):171–184. [PubMed] [Google Scholar]
  37. Schmatz D. M., Powles M. A., McFadden D. C., Pittarelli L., Balkovec J., Hammond M., Zambias R., Liberator P., Anderson J. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob Agents Chemother. 1992 Sep;36(9):1964–1970. doi: 10.1128/aac.36.9.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schmatz D. M., Romancheck M. A., Pittarelli L. A., Schwartz R. E., Fromtling R. A., Nollstadt K. H., Vanmiddlesworth F. L., Wilson K. E., Turner M. J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950–5954. doi: 10.1073/pnas.87.15.5950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schwartz R. E., Sesin D. F., Joshua H., Wilson K. E., Kempf A. J., Goklen K. A., Kuehner D., Gailliot P., Gleason C., White R. Pneumocandins from Zalerion arboricola. I. Discovery and isolation. J Antibiot (Tokyo) 1992 Dec;45(12):1853–1866. doi: 10.7164/antibiotics.45.1853. [DOI] [PubMed] [Google Scholar]
  40. Tam J. Y., Blume K. G., Prober C. G. Prophylactic fluconazole and Candida krusei infections. N Engl J Med. 1992 Mar 26;326(13):891–893. doi: 10.1056/NEJM199203263261312. [DOI] [PubMed] [Google Scholar]
  41. VanMiddlesworth F., Omstead M. N., Schmatz D., Bartizal K., Fromtling R., Bills G., Nollstadt K., Honeycutt S., Zweerink M., Garrity G. L-687,781, a new member of the papulacandin family of beta-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation, and biological activity. J Antibiot (Tokyo) 1991 Jan;44(1):45–51. doi: 10.7164/antibiotics.44.45. [DOI] [PubMed] [Google Scholar]
  42. Vanden Bossche H., Marichal P., Odds F. C. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 1994 Oct;2(10):393–400. doi: 10.1016/0966-842x(94)90618-1. [DOI] [PubMed] [Google Scholar]
  43. Whelan W. L., Kerridge D. Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans. Antimicrob Agents Chemother. 1984 Oct;26(4):570–574. doi: 10.1128/aac.26.4.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Whelan W. L., Magee P. T. Natural heterozygosity in Candida albicans. J Bacteriol. 1981 Feb;145(2):896–903. doi: 10.1128/jb.145.2.896-903.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Whelan W. L., Markie D. M., Simpkin K. G., Poulter R. M. Instability of Candida albicans hybrids. J Bacteriol. 1985 Mar;161(3):1131–1136. doi: 10.1128/jb.161.3.1131-1136.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Whelan W. L., Markie D., Kwon-Chung K. J. Complementation analysis of resistance to 5-fluorocytosine in Candida albicans. Antimicrob Agents Chemother. 1986 May;29(5):726–729. doi: 10.1128/aac.29.5.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Whelan W. L. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit Rev Microbiol. 1987;15(1):45–56. doi: 10.3109/10408418709104447. [DOI] [PubMed] [Google Scholar]
  48. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]
  49. el-Sherbeini M., Clemas J. A. Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1995 Jan;39(1):200–207. doi: 10.1128/aac.39.1.200. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES